Skip to main content

Recent Sentinel Activity

This recent activity feed provides a list of the last 90 days of Sentinel activity across assessments, publications & presentations, projects, events, etc.

RSS Feed

URL Title Category Date Recent Activity
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/counts-individuals-gout-using-urate-lowering-therapy-ult-and Counts of Individuals with Gout Using Urate-Lowering Therapy (ULT) and Switching between ULT Products: A Descriptive Analysis Modular Programs
Counts of Individuals with Gout Using Urate-Lowering Therapy (ULT) and Switching between ULT Products: A Descriptive Analysis
Modular Programs
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/risk-cardiac-congenital-malformations-following-0 Risk of Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Descriptive Analysis Modular Programs
Risk of Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Descriptive Analysis
Modular Programs
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/risk-cardiac-congenital-malformations-following-armodafinil Risk of Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis Modular Programs
Risk of Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis
Modular Programs
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/ustekinumab-dispensing-patterns-descriptive-analysis Ustekinumab Dispensing Patterns: A Descriptive Analysis Analyses
Ustekinumab Dispensing Patterns: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/serious-infections-among-immunocompromised-health-plan Serious Infections among Immunocompromised Health Plan Members Modular Programs
Serious Infections among Immunocompromised Health Plan Members
Modular Programs
https://sentinelinitiative.org/methods-data-tools/methods/covid-19-pregnancy-study-implementation COVID-19 Pregnancy Study Implementation Methods, Data, & Tools
COVID-19 Pregnancy Study Implementation
Methods, Data, & Tools
https://sentinelinitiative.org/methods-data-tools/methods/advancing-scalable-natural-language-processing-approaches-unstructured Advancing Scalable Natural Language Processing Approaches for Unstructured Electronic Health Record Data Methods, Data, & Tools
Advancing Scalable Natural Language Processing Approaches for Unstructured Electronic Health Record Data
Methods, Data, & Tools
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/pregnancy-among-women-heart-failure-descriptive-analysis Pregnancy among Women with Heart Failure: A Descriptive Analysis Modular Programs
Pregnancy among Women with Heart Failure: A Descriptive Analysis
Modular Programs
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-mothers-mother-infant-linkage-table Characterization of Mothers in the Mother-Infant Linkage Table in the Sentinel Distributed Database: A Descriptive Analysis Modular Programs
Characterization of Mothers in the Mother-Infant Linkage Table in the Sentinel Distributed Database: A Descriptive Analysis
Modular Programs
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/counts-individuals-sentinel-distributed-database Counts of Individuals in the Sentinel Distributed Database Modular Programs
Counts of Individuals in the Sentinel Distributed Database
Modular Programs
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/venous-and-arterial-thromboembolism-among-new-users-nuvaring Venous and Arterial Thromboembolism among New Users of NuvaRing and Other Combined Hormonal Contraceptives: A Descriptive Analysis Modular Programs
Venous and Arterial Thromboembolism among New Users of NuvaRing and Other Combined Hormonal Contraceptives: A Descriptive Analysis
Modular Programs
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/angioedema-following-dipeptidyl-peptidase-iv-dpp-iv Angioedema following Dipeptidyl Peptidase IV (DPP IV) Inhibitors and Angiotensin Converting Enzyme (ACE) Inhibitors Use: A Descriptive Analysis Modular Programs
Angioedema following Dipeptidyl Peptidase IV (DPP IV) Inhibitors and Angiotensin Converting Enzyme (ACE) Inhibitors Use: A Descriptive Analysis
Modular Programs
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/follow-time-guselkumab-risankizumab-and-tildrakizumab-users Follow-Up Time for Guselkumab, Risankizumab, and Tildrakizumab Users with Plaque Psoriasis: A Descriptive Analysis Modular Programs
Follow-Up Time for Guselkumab, Risankizumab, and Tildrakizumab Users with Plaque Psoriasis: A Descriptive Analysis
Modular Programs
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2016 Duration of Follow Up for New Molecular Entities Approved in 2016 Analyses
Duration of Follow Up for New Molecular Entities Approved in 2016
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2014-and Duration of Follow Up for New Molecular Entities Approved in 2014 and 2015 Analyses
Duration of Follow Up for New Molecular Entities Approved in 2014 and 2015
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2010-2012 Duration of Follow Up for New Molecular Entities Approved in 2010, 2012, and 2013 Analyses
Duration of Follow Up for New Molecular Entities Approved in 2010, 2012, and 2013
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2008-and Duration of Follow Up for New Molecular Entities Approved in 2008 and 2009 Analyses
Duration of Follow Up for New Molecular Entities Approved in 2008 and 2009
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2005-2006 Duration of Follow Up for New Molecular Entities Approved in 2005, 2006, and 2007 Analyses
Duration of Follow Up for New Molecular Entities Approved in 2005, 2006, and 2007
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2011 Duration of Follow Up for New Molecular Entities Approved in 2011 Analyses
Duration of Follow Up for New Molecular Entities Approved in 2011
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/patterns-insulin-product-use-and-billing-codes-descriptive Patterns in Insulin Product Use and Billing Codes: A Descriptive Analysis Modular Programs
Patterns in Insulin Product Use and Billing Codes: A Descriptive Analysis
Modular Programs
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-sacubitrilvalsartan-descriptive-analysis Utilization of Sacubitril/Valsartan: A Descriptive Analysis Modular Programs
Utilization of Sacubitril/Valsartan: A Descriptive Analysis
Modular Programs
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/incidence-rate-severe-uterine-bleeding-among-new-users-oral Incidence Rate of Severe Uterine Bleeding Among New Users of Oral Anticoagulants: A Descriptive Analysis Modular Programs
Incidence Rate of Severe Uterine Bleeding Among New Users of Oral Anticoagulants: A Descriptive Analysis
Modular Programs
https://sentinelinitiative.org/methods-data-tools/methods/treescan-pregnancy TreeScan in Pregnancy Methods, Data, & Tools
TreeScan in Pregnancy
Methods, Data, & Tools
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/brand-and-generic-tacrolimus-use-following-kidney-heart-and Brand and Generic Tacrolimus Use following Kidney, Heart, and Liver Transplants: A Descriptive Analysis Modular Programs
Brand and Generic Tacrolimus Use following Kidney, Heart, and Liver Transplants: A Descriptive Analysis
Modular Programs
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2017 Duration of Follow Up for New Molecular Entities Approved in 2017: A Descriptive Analysis Analyses
Duration of Follow Up for New Molecular Entities Approved in 2017: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-drugs-approved-risk-evaluation-and-mitigation Utilization of Drugs with Approved Risk Evaluation and Mitigation Strategies (REMS) that Employ Elements to Assure Safe Use (ETASU) Assessments
Utilization of Drugs with Approved Risk Evaluation and Mitigation Strategies (REMS) that Employ Elements to Assure Safe Use (ETASU)
Assessments
https://sentinelinitiative.org/methods-data-tools/methods/making-medicaid-data-more-accessible-through-common-data-models-and-fhir Making Medicaid Data More Accessible Through Common Data Models and FHIR APIs Methods, Data, & Tools
Making Medicaid Data More Accessible Through Common Data Models and FHIR APIs
Methods, Data, & Tools
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/oral-metoclopramide-use-descriptive-analysis Oral Metoclopramide Use: A Descriptive Analysis Modular Programs
Oral Metoclopramide Use: A Descriptive Analysis
Modular Programs
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/use-multiple-sclerosis-drugs-among-pregnant-women-live-birth Use of Multiple Sclerosis Drugs Among Pregnant Women with Live-Birth Deliveries: A Descriptive Analysis Assessments
Use of Multiple Sclerosis Drugs Among Pregnant Women with Live-Birth Deliveries: A Descriptive Analysis
Assessments
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/racial-differences-covid-19-outcomes-2020-2021 Racial Differences in COVID-19 Outcomes (2020-2021) Assessments
Racial Differences in COVID-19 Outcomes (2020-2021)
Assessments
https://sentinelinitiative.org/methods-data-tools/methods/development-and-illustration-framework-conducting-nonrandomized-studies Development and Illustration of a Framework for Conducting Nonrandomized Studies of Medication Safety and Effectiveness Using Healthcare Databases Methods, Data, & Tools
Development and Illustration of a Framework for Conducting Nonrandomized Studies of Medication Safety and Effectiveness Using Healthcare Databases
Methods, Data, & Tools
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/intentional-self-harm-and-hospitalized-depression-following Intentional Self-Harm and Hospitalized Depression Following Sertraline Use: A Propensity Score Matched Analysis Analyses
Intentional Self-Harm and Hospitalized Depression Following Sertraline Use: A Propensity Score Matched Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/intentional-self-harm-and-hospitalized-depression-0 Intentional Self-Harm and Hospitalized Depression Following Sertraline Use: A Propensity Score Matched Analysis (A Follow-up to a Previous Analysis) Analyses
Intentional Self-Harm and Hospitalized Depression Following Sertraline Use: A Propensity Score Matched Analysis (A Follow-up to a Previous Analysis)
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2017-updated Duration of Follow Up for New Molecular Entities Approved in 2017: An Updated Descriptive Analysis Analyses
Duration of Follow Up for New Molecular Entities Approved in 2017: An Updated Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2019 Duration of Follow Up for New Molecular Entities Approved in 2019: A Descriptive Analysis Analyses
Duration of Follow Up for New Molecular Entities Approved in 2019: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/n-nitrosodimethylamine-ndma-contaminated-and-non-ndma N‐nitrosodimethylamine (NDMA)‐Contaminated and Non‐NDMA‐Contaminated Valsartan Use: A Descriptive Analysis Analyses
N‐nitrosodimethylamine (NDMA)‐Contaminated and Non‐NDMA‐Contaminated Valsartan Use: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/tofacitinib-disease-modifying-anti-rheumatic-drugs-dmards Tofacitinib, Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and Tumor Necrosis Factor Inhibitors (TNFi) Use: A Descriptive Analysis Analyses
Tofacitinib, Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and Tumor Necrosis Factor Inhibitors (TNFi) Use: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/bleeding-events-and-venous-thromboembolism-vte-following Bleeding Events and Venous Thromboembolism (VTE) following Enoxaparin Use: A Descriptive Analysis Analyses
Bleeding Events and Venous Thromboembolism (VTE) following Enoxaparin Use: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/incidence-and-prevalence-n-nitrosodimethylamine-ndma-and-n Incidence and Prevalence of N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) Contaminated Valsartan Use: A Descriptive Analysis Analyses
Incidence and Prevalence of N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) Contaminated Valsartan Use: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/mometasone-furoate-sinus-implant-use-patients-nasal-polyps Mometasone Furoate Sinus Implant Use in Patients with Nasal Polyps: A Descriptive Analysis Analyses
Mometasone Furoate Sinus Implant Use in Patients with Nasal Polyps: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/human-epidermal-growth-factor-receptor-2-her2-antagonist-use Human Epidermal Growth Factor Receptor 2 (HER2) Antagonist Use in Patients with Live Birth Deliveries: A Descriptive Analysis Analyses
Human Epidermal Growth Factor Receptor 2 (HER2) Antagonist Use in Patients with Live Birth Deliveries: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/methods-data-tools/methods/augmenting-date-death-cause-death-ascertainment-sentinel Augmenting Date of Death & Cause of Death Ascertainment in Sentinel Methods, Data, & Tools
Augmenting Date of Death & Cause of Death Ascertainment in Sentinel
Methods, Data, & Tools
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/incident-and-prevalent-use-loop-diuretics-descriptive Incident and Prevalent Use of Loop Diuretics: A Descriptive Analysis Analyses
Incident and Prevalent Use of Loop Diuretics: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/engage-sentinel/quarterly-newsletter Quarterly Newsletter Spotlight
Quarterly Newsletter
Spotlight
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/valganciclovir-use-children-congenital-cytomegalovirus Valganciclovir Use in Children with Congenital Cytomegalovirus Disease (cCMV) or Cytomegalovirus (CMV) Infection: A Descriptive Analysis Analyses
Valganciclovir Use in Children with Congenital Cytomegalovirus Disease (cCMV) or Cytomegalovirus (CMV) Infection: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/epidiolex-prescription-cannabidiol-utilization-patterns Epidiolex (prescription cannabidiol) Utilization Patterns: A Descriptive Analysis Analyses
Epidiolex (prescription cannabidiol) Utilization Patterns: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/hydroxyurea-use-among-patients-sickle-cell-disease-scd Hydroxyurea Use Among Patients with Sickle Cell Disease (SCD): A Descriptive Analysis Analyses
Hydroxyurea Use Among Patients with Sickle Cell Disease (SCD): A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/estimated-prevalence-glomerular-diseases-descriptive Estimated Prevalence of Glomerular Diseases: A Descriptive Analysis Analyses
Estimated Prevalence of Glomerular Diseases: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/estimated-prevalence-glomerular-diseases-updated-descriptive Estimated Prevalence of Glomerular Diseases: An Updated Descriptive Analysis Analyses
Estimated Prevalence of Glomerular Diseases: An Updated Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/saphnelo-anifrolumab-fnia Assessment of ARIA Sufficiency: Saphnelo (anifrolumab-fnia) Sufficiency Assessments
Assessment of ARIA Sufficiency: Saphnelo (anifrolumab-fnia)
Sufficiency Assessments
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-brodalumab-descriptive-analysis Utilization of Brodalumab: A Descriptive Analysis Analyses
Utilization of Brodalumab: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/counts-and-characteristics-individuals-drug-device Counts and Characteristics of Individuals With Drug-Device Combination Use: A Descriptive Analysis Analyses
Counts and Characteristics of Individuals With Drug-Device Combination Use: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/duration-follow-new-molecular-entities-approved-2018 Duration of Follow Up for New Molecular Entities Approved in 2018: A Descriptive Analysis Analyses
Duration of Follow Up for New Molecular Entities Approved in 2018: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/incidence-and-prevalence-confounding-variables-over-time Incidence and Prevalence of Confounding Variables Over Time in the Sentinel Distributed Database (SDD): A Descriptive Analysis Analyses
Incidence and Prevalence of Confounding Variables Over Time in the Sentinel Distributed Database (SDD): A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/thromboembolic-stroke-major-extracranial-bleeding-0 Thromboembolic Stroke, Major Extracranial Bleeding, Gastrointestinal Bleeding, and Intracranial Hemorrhage following Direct Oral Anticoagulant Use: An Inverse Probability of Treatment Weighting Analysis Analyses
Thromboembolic Stroke, Major Extracranial Bleeding, Gastrointestinal Bleeding, and Intracranial Hemorrhage following Direct Oral Anticoagulant Use: An Inverse Probability of Treatment Weighting Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/death-data-exploration-descriptive-analysis Death Data Exploration: A Descriptive Analysis Analyses
Death Data Exploration: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-pediatric-demographics-and-enrollment Characterization of Pediatric Demographics and Enrollment in the Sentinel Distributed Database: A Descriptive Analysis Analyses
Characterization of Pediatric Demographics and Enrollment in the Sentinel Distributed Database: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/serious-infection-following-ustekinumab-use-patients-crohn-s Serious Infection Following Ustekinumab Use in Patients with Crohn’s Disease or Ulcerative Colitis: A Descriptive Analysis Analyses
Serious Infection Following Ustekinumab Use in Patients with Crohn’s Disease or Ulcerative Colitis: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/methods-data-tools/methods/approaches-handling-partially-observed-confounder-data-electronic-health Approaches to Handling Partially Observed Confounder Data From Electronic Health Records (EHR) In Non-randomized Studies of Medication Outcomes Methods, Data, & Tools
Approaches to Handling Partially Observed Confounder Data From Electronic Health Records (EHR) In Non-randomized Studies of Medication Outcomes
Methods, Data, & Tools
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/outpatient-corticosteroid-use-patients-covid-19-descriptive Outpatient Corticosteroid Use in Patients With COVID-19: A Descriptive Analysis Analyses
Outpatient Corticosteroid Use in Patients With COVID-19: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/outpatient-corticosteroid-use-patients-covid-19-updated Outpatient Corticosteroid Use in Patients With COVID-19: An Updated Descriptive Analysis Analyses
Outpatient Corticosteroid Use in Patients With COVID-19: An Updated Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/bamlanivimab-bamlanivimab-and-etesevimab-and-casirivimab Bamlanivimab, Bamlanivimab and Etesevimab, and Casirivimab-Imdevimab Use in Patients with COVID-19: A Descriptive Analysis Analyses
Bamlanivimab, Bamlanivimab and Etesevimab, and Casirivimab-Imdevimab Use in Patients with COVID-19: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterizing-pregnant-women-and-without-evidence-heart Characterizing Pregnant Women With and Without Evidence of Heart Failure and Non-Pregnant Women With Heart Failure: A Propensity Score Matched Analysis Analyses
Characterizing Pregnant Women With and Without Evidence of Heart Failure and Non-Pregnant Women With Heart Failure: A Propensity Score Matched Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/count-and-duration-follow-new-onset-cancer-updated Count and Duration of Follow up of New-Onset Cancer: An Updated Descriptive Analysis Analyses
Count and Duration of Follow up of New-Onset Cancer: An Updated Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/tacrolimus-use-patients-following-liver-or-kidney Tacrolimus Use in Patients Following Liver or Kidney Transplants: A Descriptive Analysis Analyses
Tacrolimus Use in Patients Following Liver or Kidney Transplants: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/use-monoclonal-antibodies-mabs-under-emergency-use Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: A Descriptive Analysis Analyses
Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/seizures-following-gadolinium-based-contrast-agents-exposure Seizures Following Gadolinium-Based Contrast Agents Exposure: A Self-Controlled Risk Interval Analysis Analyses
Seizures Following Gadolinium-Based Contrast Agents Exposure: A Self-Controlled Risk Interval Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-infants-mother-infant-linkage-table Characterization of Infants in the Mother-Infant Linkage Table in the Sentinel Distributed Database: A Descriptive Analysis Analyses
Characterization of Infants in the Mother-Infant Linkage Table in the Sentinel Distributed Database: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-sodium-glucose-co-transporter-2-sglt-2-inhibitor Utilization of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitor Drugs: A Descriptive Analysis Analyses
Utilization of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitor Drugs: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/hospitalization-and-anaphylaxis-following-monoclonal Hospitalization and Anaphylaxis Following Monoclonal Antibodies (mAb) Use in Patients with COVID-19: A Descriptive Analysis Analyses
Hospitalization and Anaphylaxis Following Monoclonal Antibodies (mAb) Use in Patients with COVID-19: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-obesity-drugs-descriptive-analysis Utilization of Obesity Drugs: A Descriptive Analysis Analyses
Utilization of Obesity Drugs: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/differences-covid-19-testing-positivity-hospitalization-and Differences in COVID-19 Testing, Positivity, Hospitalization, and Mortality by Race and Ethnicity in the Sentinel Distributed Database: A Descriptive Analysis Analyses
Differences in COVID-19 Testing, Positivity, Hospitalization, and Mortality by Race and Ethnicity in the Sentinel Distributed Database: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/use-monoclonal-antibodies-mabs-under-emergency-use-0 Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: An Updated Descriptive Analysis Analyses
Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: An Updated Descriptive Analysis
Analyses
https://sentinelinitiative.org/news-events/publications-presentations/racial-differences-us-covid-19-positivity-hospitalization Racial Differences in U.S. COVID-19 Positivity, Hospitalization, and Mortality Spotlight
Racial Differences in U.S. COVID-19 Positivity, Hospitalization, and Mortality
Spotlight
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/comparative-effectiveness-azithromycin-relative-roflumilast Comparative Effectiveness of Azithromycin Relative to Roflumilast in Individuals With Uncontrolled Chronic Obstructive Pulmonary Disease Despite Triple Inhaled Therapy Study Protocols & Surveillance Plan
Comparative Effectiveness of Azithromycin Relative to Roflumilast in Individuals With Uncontrolled Chronic Obstructive Pulmonary Disease Despite Triple Inhaled Therapy
Study Protocols & Surveillance Plan
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/fractures-following-leuprolide-acetate-use-multiple-factor Fractures Following Leuprolide Acetate Use: A Multiple Factor Matched Analysis (A Follow-up to a Previous Analysis) Analyses
Fractures Following Leuprolide Acetate Use: A Multiple Factor Matched Analysis (A Follow-up to a Previous Analysis)
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-ibrexafungerp-pregnant-patients-descriptive Utilization of Ibrexafungerp in Pregnant Patients: A Descriptive Analysis in TriNetX Analyses
Utilization of Ibrexafungerp in Pregnant Patients: A Descriptive Analysis in TriNetX
Analyses
https://sentinelinitiative.org/news-events/publications-presentations/data-driven-automated-classification-algorithms-acute-health Data-Driven Automated Classification Algorithms for Acute Health Conditions: Applying PheNorm to COVID-19 Disease Publications and Presentations
Data-Driven Automated Classification Algorithms for Acute Health Conditions: Applying PheNorm to COVID-19 Disease
Publications and Presentations
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-zarxio-use-signal Outcome Monitoring Following Zarxio Use: A Signal Identification Analysis Analyses
Outcome Monitoring Following Zarxio Use: A Signal Identification Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-ozempic-use-patients-type-2 Outcome Monitoring Following Ozempic Use in Patients with Type 2 Diabetes: A Signal Identification Analysis Analyses
Outcome Monitoring Following Ozempic Use in Patients with Type 2 Diabetes: A Signal Identification Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-ixekizumab-pregnant-patients-descriptive Utilization of Ixekizumab in Pregnant Patients: A Descriptive Analysis Analyses
Utilization of Ixekizumab in Pregnant Patients: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/exploring-claims-based-definitions-and-characterizing Exploring Claims-Based Definitions of, and Characterizing Patients with, Respiratory Failure: A Descriptive Analysis Analyses
Exploring Claims-Based Definitions of, and Characterizing Patients with, Respiratory Failure: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/identifying-potential-risk-factors-respiratory-failure Identifying Potential Risk Factors for Respiratory Failure: A Covariate Stratified Analysis Analyses
Identifying Potential Risk Factors for Respiratory Failure: A Covariate Stratified Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-patients-and-encounters-trinetx-live-usa Characterization of Patients and Encounters in the TriNetX Live USA Network: A Descriptive Analysis Analyses
Characterization of Patients and Encounters in the TriNetX Live USA Network: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/news-events/publications-presentations/comparative-risk-angioedema-sacubitril-valsartan-versus Comparative Risk of Angioedema with Sacubitril-Valsartan Versus Renin-Angiotensin-Aldosterone Inhibitors Publications and Presentations
Comparative Risk of Angioedema with Sacubitril-Valsartan Versus Renin-Angiotensin-Aldosterone Inhibitors
Publications and Presentations
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/cardiovascular-outcomes-following-percutaneous-transluminal Cardiovascular Outcomes Following Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) Procedures: A Descriptive Analysis Analyses
Cardiovascular Outcomes Following Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) Procedures: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/cardiovascular-outcomes-following-percutaneous Cardiovascular Outcomes Following Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) Procedures: An Updated Descriptive Analysis Analyses
Cardiovascular Outcomes Following Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) Procedures: An Updated Descriptive Analysis
Analyses
https://sentinelinitiative.org/methods-data-tools/methods/medical-literature-and-data-cannabis-use Medical Literature and Data on Cannabis Use Methods, Data, & Tools
Medical Literature and Data on Cannabis Use
Methods, Data, & Tools
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/congenital-malformations-observed-mother-s-or-linked-infant Congenital Malformations Observed in the Mother’s or Linked Infant’s Records Following Fingolimod Use During Pregnancy: A Descriptive Analysis Analyses
Congenital Malformations Observed in the Mother’s or Linked Infant’s Records Following Fingolimod Use During Pregnancy: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/congenital-malformations-observed-mother-s-records-following Congenital Malformations Observed in the Mother’s Records Following Fingolimod Use During Pregnancy: A Descriptive Analysis Analyses
Congenital Malformations Observed in the Mother’s Records Following Fingolimod Use During Pregnancy: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-zarxio-use-updated-signal Outcome Monitoring Following Zarxio Use: An Updated Signal Identification Analysis Analyses
Outcome Monitoring Following Zarxio Use: An Updated Signal Identification Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-select-biological-products-descriptive-analysis Utilization of Select Biological Products: A Descriptive Analysis Analyses
Utilization of Select Biological Products: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-select-products-migraine-treatment-and Utilization of Select Products for Migraine Treatment and Prevention: A Descriptive Analysis Analyses
Utilization of Select Products for Migraine Treatment and Prevention: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/use-gonadotropin-releasing-hormone-gnrh-agonists-patients Use of Gonadotropin-Releasing Hormone (GnRH) Agonists in Patients with Gender Dysphoria: A Descriptive Analysis Analyses
Use of Gonadotropin-Releasing Hormone (GnRH) Agonists in Patients with Gender Dysphoria: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/angioedema-following-sacubitrilvalsartan-use-patients-heart Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: A Propensity Score Analysis Analyses
Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: A Propensity Score Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/angioedema-following-sacubitrilvalsartan-use-patients-0 Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: An Updated Propensity Score Matched Analysis Analyses
Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: An Updated Propensity Score Matched Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/insulin-coding-practices-descriptive-analysis Insulin Coding Practices: A Descriptive Analysis Analyses
Insulin Coding Practices: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/brand-generic-switching-patterns-among-advair-diskus-users Brand to Generic Switching Patterns Among Advair Diskus Users with Asthma or Chronic Obstructive Pulmonary Disease (COPD): A Descriptive Analysis Analyses
Brand to Generic Switching Patterns Among Advair Diskus Users with Asthma or Chronic Obstructive Pulmonary Disease (COPD): A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-and-switching-patterns-inhaled Utilization and Switching Patterns of Inhaled Corticosteroid/Long Acting Beta Agonist and Advair Diskus in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Descriptive Analysis Analyses
Utilization and Switching Patterns of Inhaled Corticosteroid/Long Acting Beta Agonist and Advair Diskus in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/ischemic-colitis-following-alosetron-use-descriptive Ischemic Colitis Following Alosetron Use: A Descriptive Analysis Analyses
Ischemic Colitis Following Alosetron Use: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/biologics-use-adults-ulcerative-colitis-descriptive-analysis Biologics Use in Adults with Ulcerative Colitis: A Descriptive Analysis Analyses
Biologics Use in Adults with Ulcerative Colitis: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/gonadotropin-releasing-hormone-gnrh-agonists Gonadotropin-Releasing Hormone (GnRH) Agonists & Utilization Characterization Studies
Gonadotropin-Releasing Hormone (GnRH) Agonists & Utilization Characterization
Studies
https://sentinelinitiative.org/studies/drugs/zarxio-filgrastim-sndz Zarxio (Filgrastim-sndz) & Signal Identification Studies
Zarxio (Filgrastim-sndz) & Signal Identification
Studies
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/mortality-following-long-acting-injectable-antipsychotics Mortality Following Long-Acting Injectable Antipsychotics Use in Patients with Dementia: An Inverse Probability of Treatment Weighting Analysis Analyses
Mortality Following Long-Acting Injectable Antipsychotics Use in Patients with Dementia: An Inverse Probability of Treatment Weighting Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-erenumab-use-signal Outcome Monitoring Following Erenumab Use: A Signal Identification Analysis Analyses
Outcome Monitoring Following Erenumab Use: A Signal Identification Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/renal-cell-carcinoma-following-canagliflozin-use-patients Renal Cell Carcinoma Following Canagliflozin Use in Patients with Type 2 Diabetes: A Descriptive Analysis Analyses
Renal Cell Carcinoma Following Canagliflozin Use in Patients with Type 2 Diabetes: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/alosetron-and-eluxadoline-use-descriptive-analysis Alosetron and Eluxadoline Use: A Descriptive Analysis Analyses
Alosetron and Eluxadoline Use: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/dupixent-dupilumab-utilization-patterns-descriptive-analysis Dupixent (Dupilumab) Utilization Patterns: A Descriptive Analysis Analyses
Dupixent (Dupilumab) Utilization Patterns: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/prevalence-and-characterization-pharmacogenetic-testing Prevalence and Characterization of Pharmacogenetic Testing Healthcare Common Procedure Coding System (HCPCS) Procedure Codes in the Mini-Sentinel Distributed Database (MSDD): A Descriptive Analysis Analyses
Prevalence and Characterization of Pharmacogenetic Testing Healthcare Common Procedure Coding System (HCPCS) Procedure Codes in the Mini-Sentinel Distributed Database (MSDD): A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/baricitinib-or-tocilizumab-use-hospitalized-patients-covid Baricitinib or Tocilizumab Use in Hospitalized Patients with a COVID-19 Diagnosis: A Descriptive Analysis Analyses
Baricitinib or Tocilizumab Use in Hospitalized Patients with a COVID-19 Diagnosis: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-cannabis-derived-product-users-trinetx-four Characterization of Cannabis-Derived Product Users in TriNetX: Four Descriptive Analyses Analyses
Characterization of Cannabis-Derived Product Users in TriNetX: Four Descriptive Analyses
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-beta-blockers-pediatric-population-descriptive Utilization of Beta Blockers in the Pediatric Population: A Descriptive Analysis Analyses
Utilization of Beta Blockers in the Pediatric Population: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-beta-blockers-pediatric-population-updated Utilization of Beta Blockers in the Pediatric Population: An Updated Descriptive Analysis Analyses
Utilization of Beta Blockers in the Pediatric Population: An Updated Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-and-switching-patterns-mixed-amphetamine-salt Utilization and Switching Patterns of Mixed Amphetamine Salt (MAS) Products in Patients with Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy: A Descriptive Analysis Analyses
Utilization and Switching Patterns of Mixed Amphetamine Salt (MAS) Products in Patients with Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/incident-utilization-patterns-obesity-drugs-descriptive Incident Utilization Patterns of Obesity Drugs: A Descriptive Analysis Analyses
Incident Utilization Patterns of Obesity Drugs: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/methods-data-tools/methods/effectiveness-fixed-triple-combination-inhaled-corticosteroid-ics-long Effectiveness of Fixed Triple Combination Inhaled Corticosteroid (ICS), Long-Acting Beta-Agonist (LABA), and Long-Acting Muscarinic Antagonist (LAMA) Products vs. Multiple Inhaler ICS, LABA, LAMA Therapy in Patients With COPD Methods, Data, & Tools
Effectiveness of Fixed Triple Combination Inhaled Corticosteroid (ICS), Long-Acting Beta-Agonist (LABA), and Long-Acting Muscarinic Antagonist (LAMA) Products vs. Multiple Inhaler ICS, LABA, LAMA Therapy in Patients With COPD
Methods, Data, & Tools
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/incident-utilization-allopurinol-hydralazine-and Incident Utilization of Allopurinol, Hydralazine, and Propylthiouracil: A Descriptive Analysis Analyses
Incident Utilization of Allopurinol, Hydralazine, and Propylthiouracil: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/bevacizumab-and-other-cancer-medication-use-pregnant Bevacizumab and Other Cancer Medication Use in Pregnant Patients: A Descriptive Analysis Analyses
Bevacizumab and Other Cancer Medication Use in Pregnant Patients: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/baloxavir-and-oseltamivir-utilization-descriptive-analysis Baloxavir and Oseltamivir Utilization: A Descriptive Analysis Analyses
Baloxavir and Oseltamivir Utilization: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/news-events/publications-presentations/introducing-colab-evolution-us-canada-international Introducing CoLab: The Evolution of US-Canada International Collaboration on Drug Safety and Effectiveness Publications and Presentations
Introducing CoLab: The Evolution of US-Canada International Collaboration on Drug Safety and Effectiveness
Publications and Presentations
https://sentinelinitiative.org/news-events/publications-presentations/characterizing-medication-use-patterns-among-pregnant-and Characterizing Medication Use Patterns Among Pregnant and Non-Pregnant Patients with COVID-19 in the Sentinel System Publications and Presentations
Characterizing Medication Use Patterns Among Pregnant and Non-Pregnant Patients with COVID-19 in the Sentinel System
Publications and Presentations
https://sentinelinitiative.org/news-events/publications-presentations/utilization-beta-blockers-among-pediatric-population-united Utilization of Beta-blockers Among the Pediatric Population in the United States: A Study in the FDA’s Sentinel System from 2008 to 2022 Publications and Presentations
Utilization of Beta-blockers Among the Pediatric Population in the United States: A Study in the FDA’s Sentinel System from 2008 to 2022
Publications and Presentations
https://sentinelinitiative.org/news-events/publications-presentations/association-between-race-and-covid-19-outcomes-united-states Association Between Race and COVID-19 Outcomes in the United States (2020-2021) Publications and Presentations
Association Between Race and COVID-19 Outcomes in the United States (2020-2021)
Publications and Presentations
https://sentinelinitiative.org/news-events/publications-presentations/high-dose-dexamethasone-covid-19-not-common-large-us High Dose Dexamethasone for COVID-19 Not Common in a Large US Hospital Network Publications and Presentations
High Dose Dexamethasone for COVID-19 Not Common in a Large US Hospital Network
Publications and Presentations
https://sentinelinitiative.org/news-events/publications-presentations/racial-and-ethnic-differences-treatment-hospitalized-and Racial and Ethnic Differences in Treatment of Hospitalized and Critical COVID-19, January 2021 - April 2022 Publications and Presentations
Racial and Ethnic Differences in Treatment of Hospitalized and Critical COVID-19, January 2021 - April 2022
Publications and Presentations
https://sentinelinitiative.org/news-events/publications-presentations/variation-mother-infant-linkage-rates-jurisdiction-us Variation in Mother-Infant Linkage Rates by Jurisdiction in U.S. Medicaid Data Publications and Presentations
Variation in Mother-Infant Linkage Rates by Jurisdiction in U.S. Medicaid Data
Publications and Presentations
https://sentinelinitiative.org/news-events/publications-presentations/diversifying-fda-s-sentinel-system-rigorous-quality Diversifying the FDA’s Sentinel System with Rigorous Quality Inclusion Rules for the U.S. Medicaid Population Publications and Presentations
Diversifying the FDA’s Sentinel System with Rigorous Quality Inclusion Rules for the U.S. Medicaid Population
Publications and Presentations
https://sentinelinitiative.org/news-events/publications-presentations/nlp-detection-mortality-information-publicly-available-data NLP Detection of Mortality Information from Publicly Available Data Using Deep Learning Modeling Publications and Presentations
NLP Detection of Mortality Information from Publicly Available Data Using Deep Learning Modeling
Publications and Presentations
https://sentinelinitiative.org/news-events/publications-presentations/utilization-gonadotropin-releasing-hormone-agonist-products Utilization of Gonadotropin-Releasing Hormone Agonist Products in Adolescents Publications and Presentations
Utilization of Gonadotropin-Releasing Hormone Agonist Products in Adolescents
Publications and Presentations
https://sentinelinitiative.org/news-events/publications-presentations/hospitalized-arterial-and-venous-thrombotic-events-patients Hospitalized Arterial and Venous Thrombotic Events in Patients Diagnosed in the Ambulatory Setting with COVID-19 Compared to Influenza Publications and Presentations
Hospitalized Arterial and Venous Thrombotic Events in Patients Diagnosed in the Ambulatory Setting with COVID-19 Compared to Influenza
Publications and Presentations
https://sentinelinitiative.org/news-events/publications-presentations/investigating-potential-differences-safety-profiles Investigating Potential Differences in the Safety Profiles of Biosimilars Relative to Originator Products Using a Tree-Based Scan Statistic Publications and Presentations
Investigating Potential Differences in the Safety Profiles of Biosimilars Relative to Originator Products Using a Tree-Based Scan Statistic
Publications and Presentations
https://sentinelinitiative.org/news-events/publications-presentations/principled-approaches-handle-partially-observed-confounder Principled Approaches to Handle Partially Observed Confounder Data from Electronic Health Records: A Plasmode Simulation Study Publications and Presentations
Principled Approaches to Handle Partially Observed Confounder Data from Electronic Health Records: A Plasmode Simulation Study
Publications and Presentations
https://sentinelinitiative.org/news-events/publications-presentations/triple-challenges-small-sample-sizes-both-exposure-and Triple Challenges – Small Sample Sizes in Both Exposure and Control Groups When Scanning Rare Maternal Outcomes in Signal Identification: A Simulation Study Publications and Presentations
Triple Challenges – Small Sample Sizes in Both Exposure and Control Groups When Scanning Rare Maternal Outcomes in Signal Identification: A Simulation Study
Publications and Presentations
https://sentinelinitiative.org/news-events/publications-presentations/expanding-capabilities-unapproved-cannabis-derived-product Expanding Capabilities for Unapproved Cannabis-Derived Product Surveillance in the United States, TriNetX, July 1, 2018 – June 30, 2022 Publications and Presentations
Expanding Capabilities for Unapproved Cannabis-Derived Product Surveillance in the United States, TriNetX, July 1, 2018 – June 30, 2022
Publications and Presentations
https://sentinelinitiative.org/news-events/publications-presentations/exploring-use-electronic-health-records-ehr-data-active Exploring the Use of Electronic Health Records (EHR) Data for Active Safety Surveillance of Epidiolex in PCORnet, July 1, 2018 - July 1, 2022 Publications and Presentations
Exploring the Use of Electronic Health Records (EHR) Data for Active Safety Surveillance of Epidiolex in PCORnet, July 1, 2018 - July 1, 2022
Publications and Presentations
https://sentinelinitiative.org/news-events/publications-presentations/percutaneous-transluminal-septal-myocardial-ablation-and-0 Percutaneous Transluminal Septal Myocardial Ablation and Common Procedural Complications Before and After the Approval of Ablysinol Publications and Presentations
Percutaneous Transluminal Septal Myocardial Ablation and Common Procedural Complications Before and After the Approval of Ablysinol
Publications and Presentations
https://sentinelinitiative.org/news-events/publications-presentations/using-real-world-data-evaluate-comparative-effectiveness Using Real-World Data to Evaluate Comparative Effectiveness Cohorts of Azithromycin Relative to Roflumilast in Individuals with Uncontrolled Chronic Obstructive Pulmonary Disease Publications and Presentations
Using Real-World Data to Evaluate Comparative Effectiveness Cohorts of Azithromycin Relative to Roflumilast in Individuals with Uncontrolled Chronic Obstructive Pulmonary Disease
Publications and Presentations
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-products-development-pregnancy-safety-study Utilization of Products for the Development of the Pregnancy Safety Study Framework Among Mothers with Live-Birth Deliveries: A Descriptive Analysis Analyses
Utilization of Products for the Development of the Pregnancy Safety Study Framework Among Mothers with Live-Birth Deliveries: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-products-development-pregnancy-safety-study-0 Utilization of Products for the Development of the Pregnancy Safety Study Framework Among Mothers Linked to Live-Birth Deliveries in the Mother-Infant Linkage Table: A Descriptive Analysis Analyses
Utilization of Products for the Development of the Pregnancy Safety Study Framework Among Mothers Linked to Live-Birth Deliveries in the Mother-Infant Linkage Table: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-ibrexafungerp-pregnant-patients-descriptive-0 Utilization of Ibrexafungerp in Pregnant Patients: A Descriptive Analysis Analyses
Utilization of Ibrexafungerp in Pregnant Patients: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-use-biologics-and-biosimilars-sentinel Characterization of Use of Biologics and Biosimilars in the Sentinel Distributed Database: A Descriptive Analysis Analyses
Characterization of Use of Biologics and Biosimilars in the Sentinel Distributed Database: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/covid-19-hospitalization-and-severe-covid-19-infection-0 COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Inverse Probability of Treatment Weighting Analysis Analyses
COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Inverse Probability of Treatment Weighting Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-dispensing-and-coding-patterns-biologics-and Utilization, Dispensing, and Coding Patterns of Biologics and Biosimilars in the Sentinel Distributed Database: A Descriptive Analysis Analyses
Utilization, Dispensing, and Coding Patterns of Biologics and Biosimilars in the Sentinel Distributed Database: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/aimovig-erenumab-0 Aimovig (Erenumab) & Signal Identification Studies
Aimovig (Erenumab) & Signal Identification
Studies
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/racial-and-ethnic-differences-covid-19-treatment-and Racial and Ethnic Differences in COVID-19 Treatment and Mortality in TriNetX: A Descriptive Analysis Analyses
Racial and Ethnic Differences in COVID-19 Treatment and Mortality in TriNetX: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-drugs-approved-risk-evaluation-and-mitigation-0 Utilization of Drugs with Approved Risk Evaluation and Mitigation Strategies (REMS) that Employ Elements to Assure Safe Use (ETASU): A Descriptive Analysis Analyses
Utilization of Drugs with Approved Risk Evaluation and Mitigation Strategies (REMS) that Employ Elements to Assure Safe Use (ETASU): A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/ozempic-semaglutide Ozempic (Semaglutide) & Signal Identification Studies
Ozempic (Semaglutide) & Signal Identification
Studies
https://sentinelinitiative.org/news-events/publications-presentations/smdi-r-package-perform-routine-structural-missing-data SMDI: An R Package to Perform Routine Structural Missing Data Investigations in Real-World Data Publications and Presentations
SMDI: An R Package to Perform Routine Structural Missing Data Investigations in Real-World Data
Publications and Presentations
https://sentinelinitiative.org/news-events/meetings-workshops-trainings/2023-15th-annual-sentinel-initiative-public-workshop 2023 15th Annual Sentinel Initiative Public Workshop Sentinel Initiative Events
2023 15th Annual Sentinel Initiative Public Workshop
Sentinel Initiative Events
https://sentinelinitiative.org/news-events/publications-presentations/drug-safety-surveillance-ehr-data-promise-not-yet-fulfilled Drug Safety Surveillance with EHR Data: A Promise Not Yet Fulfilled Publications and Presentations
Drug Safety Surveillance with EHR Data: A Promise Not Yet Fulfilled
Publications and Presentations
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/risk-non-cardiac-congenital-malformations-following Risk of Non-Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis Analyses
Risk of Non-Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis
Analyses
https://sentinelinitiative.org/methods-data-tools/methods/monitoring-safety-and-effectiveness-covid-19-therapeutics-aim-1-protocol Monitoring of Safety and Effectiveness of COVID-19 Therapeutics: Aim 1 Protocol Development Study Protocols & Surveillance Plan
Monitoring of Safety and Effectiveness of COVID-19 Therapeutics: Aim 1 Protocol Development
Study Protocols & Surveillance Plan
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-cannabis-derived-product-users-national Characterization of Cannabis-Derived Product Users in the National Patient-Centered Clinical Research Network (PCORnet): A Descriptive Analysis Analyses
Characterization of Cannabis-Derived Product Users in the National Patient-Centered Clinical Research Network (PCORnet): A Descriptive Analysis
Analyses
https://sentinelinitiative.org/methods-data-tools/software-packages-toolkits/sentinel-views-enhancement-expanding-standardized Sentinel Views Enhancement: Expanding Standardized Dashboards to Descriptive Level 1 Analyses Methods, Data, & Tools
Sentinel Views Enhancement: Expanding Standardized Dashboards to Descriptive Level 1 Analyses
Methods, Data, & Tools
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/counts-and-characteristics-pegylated-liposomal-doxorubicin Counts and Characteristics of Pegylated Liposomal Doxorubicin and Non-Liposomal Doxorubicin Users: A Descriptive Analysis Analyses
Counts and Characteristics of Pegylated Liposomal Doxorubicin and Non-Liposomal Doxorubicin Users: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/sotyktu-deucravacitinib Assessment of ARIA Sufficiency: Sotyktu (deucravacitinib) Sufficiency Assessments
Assessment of ARIA Sufficiency: Sotyktu (deucravacitinib)
Sufficiency Assessments
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-guselkumab-risankizumab-tildrakizumab-and Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: An Updated Descriptive Analysis Analyses
Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: An Updated Descriptive Analysis
Analyses
https://sentinelinitiative.org/news-events/publications-presentations/assessing-risk-intentional-self-harm-montelukast-users Assessing the Risk of Intentional Self-Harm in Montelukast Users: An Updated Sentinel System Analysis Using ICD-10 Coding Publications and Presentations
Assessing the Risk of Intentional Self-Harm in Montelukast Users: An Updated Sentinel System Analysis Using ICD-10 Coding
Publications and Presentations
https://sentinelinitiative.org/methods-data-tools/routine-querying-tools/sentinel-routine-querying-system Sentinel Routine Querying System Methods, Data, & Tools
Sentinel Routine Querying System
Methods, Data, & Tools
https://sentinelinitiative.org/methods-data-tools/routine-querying-tools/sentinel-routine-querying-system-reporting-tool Sentinel Routine Querying System Reporting Tool Methods, Data, & Tools
Sentinel Routine Querying System Reporting Tool
Methods, Data, & Tools
https://sentinelinitiative.org/methods-data-tools/methods/development-and-refinement-toolkit-large-scale-covariate-adjustment Development and Refinement of a Toolkit for Large Scale Covariate Adjustment in the Electronic Health Record and Claims Data Partner Network Methods, Data, & Tools
Development and Refinement of a Toolkit for Large Scale Covariate Adjustment in the Electronic Health Record and Claims Data Partner Network
Methods, Data, & Tools
https://sentinelinitiative.org/news-events/publications-presentations/data-driven-automated-classification-algorithms-acute-0 Data-Driven Automated Classification Algorithms for Acute Health Conditions: Applying PheNorm to COVID-19 Disease Publications and Presentations
Data-Driven Automated Classification Algorithms for Acute Health Conditions: Applying PheNorm to COVID-19 Disease
Publications and Presentations
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/lipiodol-ethiodized-oil-and-other-non-oil-based-iodine Lipiodol (Ethiodized Oil) and Other Non-Oil Based Iodine Imaging Agent Utilization Patterns: A Descriptive Analysis Analyses
Lipiodol (Ethiodized Oil) and Other Non-Oil Based Iodine Imaging Agent Utilization Patterns: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/pediatric-use-drug-device-combinations-descriptive-analysis Pediatric Use of Drug Device Combinations: A Descriptive Analysis Analyses
Pediatric Use of Drug Device Combinations: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/bimzelx-bimekizumab-bkzx Assessment of ARIA Sufficiency: Bimzelx (bimekizumab-bkzx) Sufficiency Assessments
Assessment of ARIA Sufficiency: Bimzelx (bimekizumab-bkzx)
Sufficiency Assessments
https://sentinelinitiative.org/news-events/meetings-workshops-trainings/2024-sentinel-innovation-and-methods-seminar-series 2024 Sentinel Innovation and Methods Seminar Series Sentinel Initiative Events
2024 Sentinel Innovation and Methods Seminar Series
Sentinel Initiative Events
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/filspari-sparsentan Assessment of ARIA Sufficiency: Filspari (sparsentan) Sufficiency Assessments
Assessment of ARIA Sufficiency: Filspari (sparsentan)
Sufficiency Assessments
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/elfabrio-pegunigalsidase-alfa Assessment of ARIA Sufficiency: Elfabrio (pegunigalsidase alfa) Sufficiency Assessments
Assessment of ARIA Sufficiency: Elfabrio (pegunigalsidase alfa)
Sufficiency Assessments
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/skyclarys-omaveloxolone Assessment of ARIA Sufficiency: Skyclarys (omaveloxolone) Sufficiency Assessments
Assessment of ARIA Sufficiency: Skyclarys (omaveloxolone)
Sufficiency Assessments
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/omvoh-mirikizumab-mrkz Assessment of ARIA Sufficiency: Omvoh (mirikizumab-mrkz) Sufficiency Assessments
Assessment of ARIA Sufficiency: Omvoh (mirikizumab-mrkz)
Sufficiency Assessments
https://sentinelinitiative.org/methods-data-tools/methods/covid-19-pandemic-related-changes-healthcare-utilization-among-insured COVID-19 Pandemic Related Changes in Healthcare Utilization Among Insured Persons in the US and its Impact on Pharmacoepidemiologic Research Methods, Data, & Tools
COVID-19 Pandemic Related Changes in Healthcare Utilization Among Insured Persons in the US and its Impact on Pharmacoepidemiologic Research
Methods, Data, & Tools
https://sentinelinitiative.org/studies/drugs/glucagon-peptide-1-receptor-agonists Glucagon-Like Peptide-1 Receptor Agonists & Intentional Self-Harm Studies
Glucagon-Like Peptide-1 Receptor Agonists & Intentional Self-Harm
Studies
https://sentinelinitiative.org/news-events/fda-safety-communications-labeling-changes/update-fdas-ongoing-evaluation-reports Update on FDA's Ongoing Evaluation of Reports of Suicidal Thoughts or Actions in Patients Taking a Certain Type of Medicines Approved for Type 2 Diabetes and Obesity Regulatory Impact
Update on FDA's Ongoing Evaluation of Reports of Suicidal Thoughts or Actions in Patients Taking a Certain Type of Medicines Approved for Type 2 Diabetes and Obesity
Regulatory Impact
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/hydrochlorothiazide-use-following-labeling-update-include Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non-Melanoma Skin Cancer: A Descriptive Analysis Analyses
Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non-Melanoma Skin Cancer: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/sohonos-palovarotene Assessment of ARIA Sufficiency: Sohonos (palovarotene) Sufficiency Assessments
Assessment of ARIA Sufficiency: Sohonos (palovarotene)
Sufficiency Assessments
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/fabhalta-iptacopan Assessment of ARIA Sufficiency: Fabhalta (iptacopan) Sufficiency Assessments
Assessment of ARIA Sufficiency: Fabhalta (iptacopan)
Sufficiency Assessments
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/tzield-teplizumab-mzwv Assessment of ARIA Sufficiency: Tzield (teplizumab-mzwv) Sufficiency Assessments
Assessment of ARIA Sufficiency: Tzield (teplizumab-mzwv)
Sufficiency Assessments
https://sentinelinitiative.org/studies/devices-radiological-health/characterization-intrauterine-systems-ius-insertion-and-removal Characterization of Intrauterine Systems (IUS) Insertion and Removal and Oral Contraceptives Dispensings: A Descriptive Analysis Analyses
Characterization of Intrauterine Systems (IUS) Insertion and Removal and Oral Contraceptives Dispensings: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/methods-data-tools/health-outcomes-interest/covid-19-chart-validation-covid-19-severity-algorithm COVID-19 Chart Validation of COVID-19 Severity Algorithm Methods, Data, & Tools
COVID-19 Chart Validation of COVID-19 Severity Algorithm
Methods, Data, & Tools
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-baloxavir-use-signal Outcome Monitoring Following Baloxavir Use: A Signal Identification Analysis Analyses
Outcome Monitoring Following Baloxavir Use: A Signal Identification Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/xofluza-baloxavir Xofluza (Baloxavir) & Signal Identification Studies
Xofluza (Baloxavir) & Signal Identification
Studies
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/sezaby-phenobarbital-sodium Assessment of ARIA Sufficiency: Sezaby (phenobarbital sodium) Sufficiency Assessments
Assessment of ARIA Sufficiency: Sezaby (phenobarbital sodium)
Sufficiency Assessments
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/velsipity-etrasimod Assessment of ARIA Sufficiency: Velsipity (etrasimod) Sufficiency Assessments
Assessment of ARIA Sufficiency: Velsipity (etrasimod)
Sufficiency Assessments
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/xacduro-sulbactamdurlobactam Assessment of ARIA Sufficiency: Xacduro (sulbactam/durlobactam) Sufficiency Assessments
Assessment of ARIA Sufficiency: Xacduro (sulbactam/durlobactam)
Sufficiency Assessments
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/mixed-amphetamine-salts-immediate-release-tablet-use Mixed Amphetamine Salts Immediate-Release Tablet Use: A Descriptive Analysis Analyses
Mixed Amphetamine Salts Immediate-Release Tablet Use: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/litfulo-ritlecitinib Assessment of ARIA Sufficiency: Litfulo (ritlecitinib) Sufficiency Assessments
Assessment of ARIA Sufficiency: Litfulo (ritlecitinib)
Sufficiency Assessments
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/wainua-eplontersen Assessment of ARIA Sufficiency: Wainua (eplontersen) Sufficiency Assessments
Assessment of ARIA Sufficiency: Wainua (eplontersen)
Sufficiency Assessments
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/zavzpret-zavegepant Assessment of ARIA Sufficiency: Zavzpret (zavegepant) Sufficiency Assessments
Assessment of ARIA Sufficiency: Zavzpret (zavegepant)
Sufficiency Assessments
https://sentinelinitiative.org/news-events/publications-presentations/smdi-r-package-perform-structural-missing-data smdi: An R Package to Perform Structural Missing Data Investigations on Partially Observed Confounders in Real-world Evidence Studies Publications and Presentations
smdi: An R Package to Perform Structural Missing Data Investigations on Partially Observed Confounders in Real-world Evidence Studies
Publications and Presentations
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/vanflyta-quizartinib Assessment of ARIA Sufficiency: Vanflyta (quizartinib) Sufficiency Assessments
Assessment of ARIA Sufficiency: Vanflyta (quizartinib)
Sufficiency Assessments
https://sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/briumvi-ublituximab Assessment of ARIA Sufficiency: Briumvi (ublituximab) Sufficiency Assessments
Assessment of ARIA Sufficiency: Briumvi (ublituximab)
Sufficiency Assessments
https://sentinelinitiative.org/methods-data-tools/health-outcomes-interest/coding-trend-analyses-biopsy Coding Trend Analyses: Biopsy Methods, Data, & Tools
Coding Trend Analyses: Biopsy
Methods, Data, & Tools
https://sentinelinitiative.org/methods-data-tools/health-outcomes-interest/coding-trend-analyses-crohns-disease Coding Trend Analyses: Crohn's Disease Methods, Data, & Tools
Coding Trend Analyses: Crohn's Disease
Methods, Data, & Tools
https://sentinelinitiative.org/methods-data-tools/health-outcomes-interest/coding-trend-analyses-colectomy-colostomy-and-ileostomy Coding Trend Analyses: Colectomy, Colostomy, and Ileostomy Methods, Data, & Tools
Coding Trend Analyses: Colectomy, Colostomy, and Ileostomy
Methods, Data, & Tools
https://sentinelinitiative.org/methods-data-tools/health-outcomes-interest/coding-trend-analyses-diverticulitis-and-colitis Coding Trend Analyses: Diverticulitis and Colitis Methods, Data, & Tools
Coding Trend Analyses: Diverticulitis and Colitis
Methods, Data, & Tools
https://sentinelinitiative.org/methods-data-tools/health-outcomes-interest/coding-trend-analyses-endoscopy Coding Trend Analyses: Endoscopy Methods, Data, & Tools
Coding Trend Analyses: Endoscopy
Methods, Data, & Tools
https://sentinelinitiative.org/methods-data-tools/health-outcomes-interest/coding-trend-analyses-ulcerative-colitis Coding Trend Analyses: Ulcerative Colitis Methods, Data, & Tools
Coding Trend Analyses: Ulcerative Colitis
Methods, Data, & Tools
https://sentinelinitiative.org/methods-data-tools/methods/incorporate-range-frequently-used-engineering-features-ehrs-sentinel Incorporate a Range of Frequently Used Engineering Features from EHRs into the Sentinel Common Data Model in the Sentinel EHR and Claims Linked Data Partner Network Methods, Data, & Tools
Incorporate a Range of Frequently Used Engineering Features from EHRs into the Sentinel Common Data Model in the Sentinel EHR and Claims Linked Data Partner Network
Methods, Data, & Tools
https://sentinelinitiative.org/news-events/publications-presentations/risk-arterial-and-venous-thrombotic-events-among-patients Risk of Arterial and Venous Thrombotic Events Among Patients with COVID-19: A Multi-National Collaboration of Regulatory Agencies from Canada, Europe, and United States Publications and Presentations
Risk of Arterial and Venous Thrombotic Events Among Patients with COVID-19: A Multi-National Collaboration of Regulatory Agencies from Canada, Europe, and United States
Publications and Presentations
https://sentinelinitiative.org/news-events/publications-presentations/process-guide-inferential-studies-using-healthcare-data Process Guide for Inferential Studies Using Healthcare Data from Routine Clinical Practice to Evaluate Causal Effects of Drugs (PRINCIPLED): Considerations from the FDA Sentinel Innovation Center Publications and Presentations
Process Guide for Inferential Studies Using Healthcare Data from Routine Clinical Practice to Evaluate Causal Effects of Drugs (PRINCIPLED): Considerations from the FDA Sentinel Innovation Center
Publications and Presentations
https://sentinelinitiative.org/methods-data-tools/sentinel-common-data-model/sentinel-common-data-model Sentinel Common Data Model Methods, Data, & Tools
Sentinel Common Data Model
Methods, Data, & Tools
https://sentinelinitiative.org/methods-data-tools/methods/empirical-application-sentinel-ehr-and-claims-data-partner-network Empirical Application of the Sentinel EHR and Claims Data Partner Network to Enhance ARIA Sufficient Inferential Requests and Atypical Descriptive Requests (Use Case Package 2) Methods, Data, & Tools
Empirical Application of the Sentinel EHR and Claims Data Partner Network to Enhance ARIA Sufficient Inferential Requests and Atypical Descriptive Requests (Use Case Package 2)
Methods, Data, & Tools
https://sentinelinitiative.org/studies/drugs/dupixent-dupilumab Dupixent (Dupilumab) & Signal Identification Studies
Dupixent (Dupilumab) & Signal Identification
Studies
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-dupilumab-use-signal Outcome Monitoring Following Dupilumab Use: A Signal Identification Analysis Analyses
Outcome Monitoring Following Dupilumab Use: A Signal Identification Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/individual-drug-analyses/sodium-glucose-cotransporter-2-sglt2-inhibitor-use-patients Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Use in Patients with Diabetes Mellitus: A Descriptive Analysis Analyses
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Use in Patients with Diabetes Mellitus: A Descriptive Analysis
Analyses
https://sentinelinitiative.org/studies/drugs/olumiant-baricitinib-and-actemra-tocilizumab Olumiant (Baricitinib) and Actemra (Tocilizumab) & Emergency Use Authorization (EUA) Utilization Studies
Olumiant (Baricitinib) and Actemra (Tocilizumab) & Emergency Use Authorization (EUA) Utilization
Studies
https://sentinelinitiative.org/studies/drugs/pre-pen-plus-benzylpenicilloyl-polylysine Pre-Pen Plus (Benzylpenicilloyl Polylysine) & Skin Test Antigen Utilization Studies
Pre-Pen Plus (Benzylpenicilloyl Polylysine) & Skin Test Antigen Utilization
Studies
https://sentinelinitiative.org/studies/drugs/provigil-modafinil-and-nuvigil-armodafinil-0 Provigil (Modafinil) and Nuvigil (Armodafinil) & Congenital Cardiac and Non-Cardiac Malformations Studies
Provigil (Modafinil) and Nuvigil (Armodafinil) & Congenital Cardiac and Non-Cardiac Malformations
Studies
https://sentinelinitiative.org/studies/drugs/dupixent-dupilumab-0 Dupixent (Dupilumab) & Indications for Use Studies
Dupixent (Dupilumab) & Indications for Use
Studies
https://sentinelinitiative.org/news-events/meetings-workshops-trainings/process-guide-inferential-studies-using-healthcare-data A PRocess guide for INferential studies using healthcare data from routine ClinIcal Practice to evaLuate causal Effects of Drugs (PRINCIPLED) Sentinel Initiative Events 02/29/2024
A PRocess guide for INferential studies using healthcare data from routine ClinIcal Practice to evaLuate causal Effects of Drugs (PRINCIPLED)
Sentinel Initiative Events
https://sentinelinitiative.org/news-events/meetings-workshops-trainings/data-driven-phenotyping-algorithms-acute-health-conditions Data-driven Phenotyping Algorithms for Acute Health Conditions: Applying PheNorm to COVID-19 Sentinel Initiative Events 03/25/2024
Data-driven Phenotyping Algorithms for Acute Health Conditions: Applying PheNorm to COVID-19
Sentinel Initiative Events